Lantheus Holdings, Inc. with ticker code (LNTH) have now 10 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $165.00 and $125.00 calculating the average target price we see $142.40. Now with the previous closing price of $109.71 this is indicating there is a potential upside of 29.8%. The 50 day MA is $99.61 and the 200 moving average now moves to $74.40. The total market capitalization for the company now stands at 7.28B. Currently the stock stands at: $104.81 USD
The potential market cap would be $9,445,336,037 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 17.24, revenue per share of $20.91 and a 17.41% return on assets.
Lantheus Holdings, Inc. is an integrated provider of imaging diagnostics, targeted therapeutics, and artificial intelligence solutions to find, fight and follow serious medical conditions. The Company’s products include precision diagnostics, radiopharmaceutical oncology, and strategic partnerships. Its precision diagnostic products assist healthcare professionals (HCPs) Find and Follow diseases, with a focus on cardiology. Its radiopharmaceutical oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Its strategic partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes the Company’s license of RELISTOR to Bausch Health Companies, Inc. (Bausch). Its commercial products are used by oncologists, urologists, nuclear medicine physicians, cardiologists, sonographers, technologists, radiologists, and internal medicine physicians working in a variety of clinical settings.
